Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

New and emerging therapies for acute and chronic graft versus host disease.

Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E.

Ther Adv Hematol. 2018 Jan;9(1):21-46. doi: 10.1177/2040620717741860. Epub 2017 Nov 28. Review.

2.

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.

Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP.

Nat Commun. 2017 Dec 18;8(1):2166. doi: 10.1038/s41467-017-02390-7.

3.

Amatuximab and novel agents targeting mesothelin for solid tumors.

Baldo P, Cecco S.

Onco Targets Ther. 2017 Nov 8;10:5337-5353. doi: 10.2147/OTT.S145105. eCollection 2017. Review.

4.

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy.

Montana W, Buck DA, Smith T.

Case Rep Oncol. 2017 Sep 6;10(3):795-801. doi: 10.1159/000479224. eCollection 2017 Sep-Dec.

5.

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

Xu Y, Jin S, Zhao W, Liu W, Ding D, Zhou J, Chen S.

Int J Mol Sci. 2017 Oct 31;18(11). pii: E2284. doi: 10.3390/ijms18112284.

6.

Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.

Schönberger S, van Beekum C, Götz B, Nettersheim D, Schorle H, Schneider DT, Casati A, Craveiro RB, Calaminus G, Dilloo D.

J Cell Mol Med. 2018 Jan;22(1):568-575. doi: 10.1111/jcmm.13344. Epub 2017 Sep 22.

7.

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Ryan MC, Palanca-Wessels MC, Schimpf B, Gordon KA, Kostner H, Meyer B, Yu C, Van Epps HA, Benjamin D.

Blood. 2017 Nov 2;130(18):2018-2026. doi: 10.1182/blood-2017-04-779389. Epub 2017 Sep 13.

8.

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM.

Blood Cancer J. 2017 Sep 8;7(9):e603. doi: 10.1038/bcj.2017.85. Review.

9.

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J.

Drug Des Devel Ther. 2017 Aug 2;11:2265-2276. doi: 10.2147/DDDT.S135571. eCollection 2017. Review.

10.

Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.

Woitok M, Klose D, Di Fiore S, Richter W, Stein C, Gresch G, Grieger E, Barth S, Fischer R, Kolberg K, Niesen J.

Onco Targets Ther. 2017 Jul 6;10:3313-3327. doi: 10.2147/OTT.S140492. eCollection 2017.

11.

Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles.

Kernan DL, Wen AM, Pitek AS, Steinmetz NF.

Exp Biol Med (Maywood). 2017 Aug;242(14):1405-1411. doi: 10.1177/1535370217719222. Epub 2017 Jul 4.

PMID:
28675044
12.

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma.

Tudesq JJ, Vincent L, Lebrun J, Hicheri Y, Gabellier L, Busetto T, Merle C, Fegueux N, Ceballos P, Quittet P, Navarro R, Hillaire-Buys D, Cartron G.

Open Forum Infect Dis. 2017 Apr 5;4(2):ofx091. doi: 10.1093/ofid/ofx091. eCollection 2017 Spring.

13.

RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.

Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, Heibeck TH, Tran C, Masikat MR, Zhou S, Stafford RL, Yam AY, Lee J, Steiner AR, Gill A, Penta K, Pollitt S, Baliga R, Murray CJ, Thanos CD, McEvoy LM, Sato AK, Hallam TJ.

Sci Rep. 2017 Jun 8;7(1):3026. doi: 10.1038/s41598-017-03192-z.

14.

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.

Nielsen CF, van Putten SM, Lund IK, Melander MC, Nørregaard KS, Jürgensen HJ, Reckzeh K, Christensen KR, Ingvarsen SZ, Gårdsvoll H, Jensen KE, Hamerlik P, Engelholm LH, Behrendt N.

Oncotarget. 2017 Jul 4;8(27):44605-44624. doi: 10.18632/oncotarget.17883.

15.

Conjugates of Small Molecule Drugs with Antibodies and Other Proteins.

Feng Y, Zhu Z, Chen W, Prabakaran P, Lin K, Dimitrov DS.

Biomedicines. 2014 Jan 24;2(1):1-13. doi: 10.3390/biomedicines2010001. Review.

16.

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

Li H, Han TH, Hunder NN, Jang G, Zhao B.

J Clin Pharmacol. 2017 Sep;57(9):1148-1158. doi: 10.1002/jcph.920. Epub 2017 May 17.

17.

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates

Abdollahpour-Alitappeh M, Lotfinia M, Razavi-Vakhshourpour S, Jahandideh S, Najminejad H, Sineh Sepehr K, Moazami R, Shams E, Habibi-Anbouhi M, Abolhassani M.

Iran Biomed J. 2017 Jul;21(4):270-4. Epub 2017 Apr 15.

18.

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS.

JMIR Res Protoc. 2017 Mar 20;6(3):e45. doi: 10.2196/resprot.7289.

19.

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.

Int J Mol Sci. 2017 Feb 14;18(2). pii: E401. doi: 10.3390/ijms18020401.

20.

Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Howard D, Garcia-Parra J, Healey GD, Amakiri C, Margarit L, Francis LW, Gonzalez D, Conlan RS.

Interface Focus. 2016 Dec 6;6(6):20160054. Review.

Supplemental Content

Support Center